# US 2021/0275646 A1 · Pharmacologic treatment for right ventricular failure

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275646 A1
- Document ID: US20210275646A1
- Status: Published application
- Kind: A1
- Application number: 17/245,531
- Filed: 2021-04-30
- Published: 2021-09-09
- Earliest claimed: 2018-11-02
- Applicants: The Trustees of Columbia University in the City of New York
- Inventors: Emily Joy Tsai; Christos Tzimas
- Web page: https://patentgrep.com/patent/US20210275646A1

## CPC

- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- C12Q 1/6883: for diseases caused by alterations of genetic material
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 35/761: Adenovirus
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12Q 2600/158: Expression markers
- G01N 2800/32: Cardiovascular disorders
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure provides, inter alia, methods for treating or ameliorating the effect of a cardiopulmonary disease, including right ventricular failure (RVF), in a subject. Also provided are methods for diagnosing the risk of having RVF in a subject, methods for preventing RVF in a subject, methods for preventing non-canonical autophagy, methods for mitigating oxidative stress in mitochondria of a cell, and methods for inhibiting microtubule-mediated active mRNA transfer in a cell. A pharmaceutical composition and treatment methods using such composition are also provided.

## Claims

### Claim 1

A method for treating or ameliorating the effect of a cardiopulmonary disease in a subject, comprising modulating the expression of at least one gene of a gene module associated with right ventricular failure (RVF) in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the gene module comprises the following genes: WIPI1, HSPB6, MAP4, SNAP47, and PRDX.

### Claim 3 (depends on 1)

The method of claim 1, wherein the modulation comprises decreasing the expression of at least one of WIPI1, HSPB6, MAP4, and SNAP47, and/or increasing the expression of PRDX, in the subject.

### Claim 4 (depends on 1)

The method of claim 1, wherein the modulation comprises decreasing the expression of WIPI1, HSPB6, and MAP4, in the subject.

### Claim 5 (depends on 1)

The method of claim 1, wherein the modulation comprises decreasing the expression of WIPI1, in the subject.

### Claim 6 (depends on 1)

The method of claim 1, wherein the cardiopulmonary disease is associated with right ventricular failure (RVF).

### Claim 7 (depends on 1)

The method of claim 1, wherein the cardiopulmonary disease is selected from heart failure and pulmonary hypertension.

### Claim 8

A method for diagnosing right ventricular failure (RVF) in a subject, comprising:
(a) obtaining a biological sample from the subject;
(b) determining the expression level of at least one gene of a gene module in the sample and comparing it to a reference determined in a healthy subject;
(c) diagnosing the subject as being at risk for right ventricular failure (RVF) if the expression level of the at least one gene of the gene module in the sample is significantly higher than the reference; and
(d) initiating a treatment protocol for the subject diagnosed in step (c) as being at risk for RVF.

### Claim 9 (depends on 8)

The method of claim 8, wherein the gene module comprises the following genes: WIPI1, HSPB6, MAP4.

### Claim 10 (depends on 8)

The method of claim 8, wherein the at least one gene is WIPI1.

### Claim 11 (depends on 8)

The method of claim 8, wherein the treatment protocol comprises modulating WIPI1 expression.

### Claim 12

A method for preventing right ventricular failure (RVF) in a subject, comprising decreasing the expression of WIPI1, in the subject.

### Claim 13 (depends on 12)

The method of claim 12, wherein the subject has at least one of the following: right ventricular dysfunction (RVD), reduced ejection fraction, preserved ejection fraction, a left ventricular assist device, pulmonary hypertension, and cardiovascular etiology.

### Claim 14

A method for preventing non-canonical autophagy in a cardiac myocyte, comprising decreasing the expression of WIPI1, in the cardiac myocyte.

### Claim 15 (depends on 14)

The method of claim 14, wherein the non-canonical autophagy is induced by a neurohormone.

### Claim 16 (depends on 15)

The method of claim 15, wherein the neurohormone is aldosterone.

### Claim 17

A method for mitigating oxidative stress in mitochondria of a cardiac myocyte, comprising decreasing the expression of WIPI1, in the cardiac myocyte.

### Claim 18 (depends on 17)

The method of claim 17, wherein the oxidative stress is aldosterone-induced.

### Claim 19 (depends on 17)

The method of claim 17, wherein the oxidative stress is not induced by hydrogen peroxide.

### Claim 20

A pharmaceutical composition comprising: a first vector expressing CRISPR associated protein 9 (CAS9), a second vector expressing WIPI1 gRNA, and a pharmaceutically acceptable carrier.

### Claim 21 (depends on 20)

A method for treating or ameliorating the effect of a cardiopulmonary disease in a subject, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition according to claim 20.
